Literature DB >> 2145067

An open-label trial of milacemide in schizophrenia: an NMDA intervention strategy.

R B Rosse1, B L Schwartz, M P Leighton, R E Davis, S I Deutsch.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2145067     DOI： 10.1097/00002826-199008000-00010

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN： 0362-5664            Impact factor:   1.592


× No keyword cloud information.
  8 in total

Review 1.  Recent advances in targeting the ionotropic glutamate receptors in treating schizophrenia.

Authors:  Robert E McCullumsmith; John Hammond; Adam Funk; James H Meador-Woodruff
Journal:  Curr Pharm Biotechnol       Date:  2012-06       Impact factor: 2.837

Review 2.  Mechanisms of action of atypical antipsychotic drugs: a critical analysis.

Authors:  B J Kinon; J A Lieberman
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

Review 3.  International Union of Basic and Clinical Pharmacology. XCVIII. Histamine Receptors.

Authors:  Pertti Panula; Paul L Chazot; Marlon Cowart; Ralf Gutzmer; Rob Leurs; Wai L S Liu; Holger Stark; Robin L Thurmond; Helmut L Haas
Journal:  Pharmacol Rev       Date:  2015-07       Impact factor: 25.468

4.  The contribution of the different binding sites of the N-methyl-D-aspartate (NMDA) receptor to the expression of behavior.

Authors:  B D Kretschmer; B Zadow; T L Volz; L Volz; W J Schmidt
Journal:  J Neural Transm Gen Sect       Date:  1992

Review 5.  Potentiation of the NMDA receptor in the treatment of schizophrenia: focused on the glycine site.

Authors:  Seong S Shim; Michael D Hammonds; Baik S Kee
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2007-09-27       Impact factor: 5.270

6.  d-cycloserine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label study.

Authors:  N G Cascella; F Macciardi; C Cavallini; E Smeraldi
Journal:  J Neural Transm Gen Sect       Date:  1994

7.  Effects of D-cycloserine and (+)-HA-966 on the locomotor stimulation induced by NMDA antagonists and clonidine in monoamine-depleted mice.

Authors:  M L Carlsson; G Engberg; A Carlsson
Journal:  J Neural Transm Gen Sect       Date:  1994

Review 8.  Glutamate receptor abnormalities in schizophrenia: implications for innovative treatments.

Authors:  Maria D Rubio; Jana B Drummond; James H Meador-Woodruff
Journal:  Biomol Ther (Seoul)       Date:  2012-01       Impact factor: 4.634
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.